| Identification | Back Directory | [Name]
Benzo[b]thiophene-3-carbonitrile, 2-amino-4,5,6,7-tetrahydro-4-methyl-4-[5-[4-[(1S)-1-[(2S)-1-methyl-2-pyrrolidinyl]ethoxy]-6-[[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]oxy]-2-pyrimidinyl]-3-isoxazolyl]-, (4S)- | [CAS]
2749963-77-5 | [Synonyms]
KRAS G12C inhibitor 56
Benzo[b]thiophene-3-carbonitrile, 2-amino-4,5,6,7-tetrahydro-4-methyl-4-[5-[4-[(1S)-1-[(2S)-1-methyl-2-pyrrolidinyl]ethoxy]-6-[[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]oxy]-2-pyrimidinyl]-3-isoxazolyl]-, (4S)- | [Molecular Formula]
C32H39N7O4S | [MOL File]
2749963-77-5.mol | [Molecular Weight]
617.76 |
| Hazard Information | Back Directory | [Uses]
KRAS G12C inhibitor 56 (compound IC-6) is a potent SOS1 inhibitor with an IC50 of 1.6 nM. KRAS G12C inhibitor 56 can be used in cancer research[1]. | [References]
[1] Jason ABBOTT, et al. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer. Patent WO2021245051A1. |
|
|